Table 2:

Clinical scales of baseline and month 12 (median and range)^{^a}

Time Point	Baseline		Month 12		P Value
Patients on natalizumab
EDSS	3.0	(1.5–6.5)	3.0	(1.0–6.5)	1.0
HADS-A	6.0	(1–13)	6.0	(0–15)	1.0
HADS-D	4.5	(0–18)	2.0	(0–17)	.012^{^b}
CIS-20	68.5	(14–125)	62.0	(10–117)	.036
Patients on IFNb/GA (n = 17)
EDSS	2.5	(1.0–6.5)	3.0	(1.5–7.0)	.006^{^b}
HADS-A	7.0	(1–14)	5.0	(1–11)	.609
HADS-D	5.0	(0–12)	3.0	(0–14)	.855
CIS-20	86.0	(31–114)	81.0	(16–105)	.177
Healthy controls (n = 12)
HADS-A	3.5	(1–12)	2.5	(0–9)	1.0
HADS-D	1.0	(0–10)	0.0	(0–5)	1.0
CIS-20	42.5	(17–85)	52.0	(17–82)	.744

Note:—CIS-20 indicates Checklist Individual Strength questionnaire; HADS, Hospital Anxiety and Depression Scale; A, Anxiety; D, Depression.
↵a EDSS, HADS, and CIS were tested with the related-samples Wilcoxon signed rank test (Bonferroni-corrected).
↵b Significant difference.